Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling.
Abe Y, Sakata-Yanagimoto M, Fujisawa M, Miyoshi H, Suehara Y, Hattori K, Kusakabe M, Sakamoto T, Nishikii H, Nguyen TB, Owada Y, Enomoto T, Sawa A, Bando H, Yoshida C, Tabata R, Terao T, Nakayama M, Ohshima K, Usuki K, Oda T, Matsue K, Chiba S. Abe Y, et al. Among authors: yoshida c. Nat Cell Biol. 2022 Apr;24(4):565-578. doi: 10.1038/s41556-022-00866-3. Epub 2022 Mar 24. Nat Cell Biol. 2022. PMID: 35332263 Free PMC article.
[Acquired platelet dysfunction with severe bleeding tendency in triple-negative myelofibrosis].
Momose H, Nishikii H, Kozuma Y, Ota-Tsutsumi I, Nannya Y, Yoshida C, Komeno T, Kusakabe M, Yokoyama Y, Kato T, Kurita N, Sootome A, Sakata-Yanagimoto M, Obara N, Hasegawa Y, Ogawa S, Chiba S. Momose H, et al. Among authors: yoshida c. Rinsho Ketsueki. 2021;62(9):1406-1411. doi: 10.11406/rinketsu.62.1406. Rinsho Ketsueki. 2021. PMID: 34615801 Japanese.
Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML, Shimousa Hematology Study Groups. Kumagai T, et al. Among authors: yoshida c. Cancer Sci. 2020 Aug;111(8):2923-2934. doi: 10.1111/cas.14518. Epub 2020 Jun 26. Cancer Sci. 2020. PMID: 32614159 Free PMC article. Clinical Trial.
Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.
Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML and Shimousa Hematology Study Groups. Kumagai T, et al. Among authors: yoshida c. Cancer Sci. 2018 Jan;109(1):182-192. doi: 10.1111/cas.13430. Epub 2017 Nov 29. Cancer Sci. 2018. PMID: 29058817 Free PMC article. Clinical Trial.
Cytotoxic T-cell lymphoma arising in Behçet disease.
Katsura Y, Suzukawa K, Kojima H, Yoshida C, Shimizu S, Mukai H, Hasegawa Y, Imagawa S, Mori N, Nagasawa T. Katsura Y, et al. Among authors: yoshida c. Int J Hematol. 2003 Apr;77(3):282-5. doi: 10.1007/BF02983787. Int J Hematol. 2003. PMID: 12731673 Review.
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Iriyama N, et al. Among authors: yoshida c. Am J Hematol. 2015 Apr;90(4):282-7. doi: 10.1002/ajh.23923. Epub 2015 Mar 2. Am J Hematol. 2015. PMID: 25530131 Free article. Clinical Trial.
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Iriyama N, et al. Among authors: yoshida c. Am J Hematol. 2015 Sep;90(9):819-24. doi: 10.1002/ajh.24096. Am J Hematol. 2015. PMID: 26103598 Free article. Clinical Trial.
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. Najima Y, et al. Among authors: yoshida c. Leuk Res. 2018 Mar;66:66-72. doi: 10.1016/j.leukres.2018.01.010. Epub 2018 Feb 3. Leuk Res. 2018. PMID: 29407585 Clinical Trial.
599 results